Sudden Hearing Loss Recovery with Diabetes Case

A 56-year-old woman with severely uncontrolled type 2 diabetes experienced a sudden, significant hearing loss in her right ear. Despite the known risks of using high-dose steroids in such a metabolic state, her medical team proceeded with the standard treatment. Within a week, her hearing returned to normal. A recent case report details this clinical scenario, illustrating the potential for full-dose corticosteroid therapy even in patients with poorly controlled diabetes when managed with aggressive glucose monitoring.

Defining the Therapeutic Dilemma in Sudden Hearing Loss

Sudden sensorineural hearing loss (SSNHL) is an otologic emergency. It is defined as a hearing decline of at least 30 decibels across three connected frequencies, occurring within a 72-hour window. The established first-line treatment is a course of high-dose corticosteroids. However, type 2 diabetes mellitus is a well-documented risk factor for SSNHL and, paradoxically, a predictor of poorer recovery from it. This creates a significant conflict for clinicians: the primary treatment is known to dangerously elevate blood glucose, yet the condition it treats is more common and severe in the very patients for whom the treatment is most hazardous.

Case Methodology: Treating Against Conventional Wisdom

The patient, a 56-year-old woman, presented two days after the onset of right-sided hearing loss. Her type 2 diabetes was severely uncontrolled, with an HbA1c level exceeding 14%. She also had hypercholesterolaemia. Audiometric testing confirmed a moderate-to-severe SSNHL in her right ear.

Faced with this dilemma, the treating team, led by Ni Made Pasmiati Setyaningsih and Ni Putu Oktaviani Rinika Pranitasari, opted for a multi-pronged approach. They initiated the standard intravenous methylprednisolone taper over 15 days. This was supported by five sessions of hyperbaric oxygen therapy and statin medication. Crucially, they simultaneously engaged an endocrinology team to manage her diabetes with a basal-bolus insulin regimen. Her capillary glucose was monitored intensively, with readings exceeding the glucometer’s upper limit of 500 mg/dL on four occasions; the highest measurable value was 496 mg/dL. Hyperglycaemia was managed by adjusting insulin doses upward, not by reducing or stopping the corticosteroid.

Findings: Complete Hearing Recovery Despite Extreme Hyperglycaemia

The outcome was striking. The patient’s hearing thresholds returned to the normal range by the seventh day of treatment. They remained normal when rechecked on day twelve, meeting the criteria for complete recovery according to modified Siegel’s criteria. No clinical hyperglycaemic crisis, such as diabetic ketoacidosis, occurred during the treatment period.

The authors note that causal attribution is impossible from a single case. The patient had several factors associated with a better prognosis, including hyperlipidaemia (treated with statins) and the addition of hyperbaric oxygen therapy. The recovery cannot be definitively pinned on the corticosteroid regimen alone. However, the case demonstrates that administering the full, standard steroid course was not an automatic barrier to recovery in this high-risk patient. You can read the full case report here.

Practical Implications for Hearing and Metabolic Health

This report has immediate implications for clinical practice. It suggests that severe, uncontrolled diabetes should not be an absolute contraindication to corticosteroid treatment for SSNHL. The feasibility hinges on a structured, proactive management plan.

The critical elements were real-time glucose monitoring and a pre-arranged collaboration with endocrinology specialists who could aggressively titrate insulin. The therapy proceeded without interruption, which may be vital for its efficacy in salvaging hearing. This model of co-management could be applied in other settings where necessary treatments worsen chronic conditions. For instance, similar interdisciplinary care is often needed for patients with TMD linked to various ear and hearing disorders.

Connections to Broader Hearing and Neurological Research

This case sits at the intersection of auditory, metabolic, and inflammatory pathways. Sudden hearing loss itself is often studied alongside other neurotological conditions. For example, researchers are actively exploring the inflammatory and vascular links in disorders like migraine-related tinnitus and vestibular symptoms. The use of hyperbaric oxygen in this case also points to the ongoing investigation of pressure-based therapies for inner ear disorders, similar to those explored in a study on bilateral Ménière’s disease.

The takeaway is not that steroids are safe in uncontrolled diabetes, but that their risk can be managed in a hospital setting with expert support. For patients, this underscores the importance of disclosing all health conditions, especially metabolic ones like diabetes, immediately during an auditory emergency. It also highlights the value of integrated care between otology, audiology, and endocrinology for achieving the best possible hearing health outcomes.